Ann: Quarterly Activity Report - 30 June 2022, page-19

Hey mitgar would be keen to hear your feedback once local sales/distribution conversation commences. From the sales growth and Judith's commentary it is rather clear that most surgeons in the US are still only applying Xperience for their high risk patients, so there needs to be abit more convincing to do (whether it's data or growing comfort of product use over time) for them to apply it across all their surgery list, suspect this also has to do with the cost discussion within hospitals. Anyway keen to know whether the same issue comes up here in Aus!